BR112022019041A2 - Inibidores de kcnt1 e métodos de uso - Google Patents
Inibidores de kcnt1 e métodos de usoInfo
- Publication number
- BR112022019041A2 BR112022019041A2 BR112022019041A BR112022019041A BR112022019041A2 BR 112022019041 A2 BR112022019041 A2 BR 112022019041A2 BR 112022019041 A BR112022019041 A BR 112022019041A BR 112022019041 A BR112022019041 A BR 112022019041A BR 112022019041 A2 BR112022019041 A2 BR 112022019041A2
- Authority
- BR
- Brazil
- Prior art keywords
- kcnt1
- methods
- inhibitors
- disease
- disorder
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062993359P | 2020-03-23 | 2020-03-23 | |
| PCT/US2021/023653 WO2021195066A2 (en) | 2020-03-23 | 2021-03-23 | Kcnt1 inhibitors and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022019041A2 true BR112022019041A2 (pt) | 2022-12-27 |
Family
ID=77892612
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022019041A BR112022019041A2 (pt) | 2020-03-23 | 2021-03-23 | Inibidores de kcnt1 e métodos de uso |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230285377A1 (https=) |
| EP (1) | EP4125831A4 (https=) |
| JP (1) | JP7838820B2 (https=) |
| KR (1) | KR20230005168A (https=) |
| CN (2) | CN121868303A (https=) |
| AU (1) | AU2021241530A1 (https=) |
| BR (1) | BR112022019041A2 (https=) |
| CA (1) | CA3176609A1 (https=) |
| IL (1) | IL296649A (https=) |
| MX (2) | MX2022011813A (https=) |
| WO (1) | WO2021195066A2 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20250172745A (ko) * | 2019-05-03 | 2025-12-09 | 프락시스 프리시젼 메디신즈, 인크. | Kcnt1 억제제 및 사용 방법 |
| KR20220016086A (ko) * | 2019-05-03 | 2022-02-08 | 프락시스 프리시젼 메디신즈, 인크. | Kcnt1 억제제 및 사용 방법 |
| JP7699836B2 (ja) | 2020-02-28 | 2025-06-30 | プラクシス プレシジョン メディシンズ， インコーポレイテッド | Ｋｃｎｔ１阻害剤、および使用方法 |
| US11773088B2 (en) | 2020-11-02 | 2023-10-03 | Praxis Precision Medicines, Inc. | KCNT1 inhibitors and methods of use |
| WO2023211854A1 (en) * | 2022-04-25 | 2023-11-02 | Praxis Precision Medicines, Inc. | Kcnt1 inhibitors comprising a thiazole core and methods of use |
| WO2023211850A1 (en) * | 2022-04-25 | 2023-11-02 | Praxis Precision Medicines, Inc. | Kcnt1 inhibitors comprising an isoxazole or oxadiazole core and methods of use |
| IL316283A (en) * | 2022-04-25 | 2024-12-01 | Praxis Prec Medicines Inc | KCNT1 inhibitors comprising a pyrazole core and methods of use |
| EP4630399A1 (en) * | 2022-12-05 | 2025-10-15 | Praxis Precision Medicines, Inc. | Kcnt1 inhibitors comprising a phenyl, pyridine, or pyrimidine core and methods of use |
| TW202502311A (zh) * | 2023-03-29 | 2025-01-16 | 美商默沙東有限責任公司 | Il4i1抑制劑及其使用方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003221322A1 (en) * | 2002-03-07 | 2003-09-16 | Sds Biotech K.K. | Substituted isoxazole alkylamine derivative and agri- and horticultural fungicide |
| KR101195801B1 (ko) * | 2004-06-18 | 2012-11-05 | 밀레니엄 파머슈티컬스 인코퍼레이티드 | Ｘａ 인자 억제제 |
| ATE478847T1 (de) * | 2006-09-15 | 2010-09-15 | Pfizer | Substituierte pyridylmethylbicyclocarboxyamidverbindungen |
| US9321727B2 (en) * | 2011-06-10 | 2016-04-26 | Hoffmann-La Roche Inc. | Pyridine derivatives as agonists of the CB2 receptor |
| TW201642855A (zh) * | 2015-03-10 | 2016-12-16 | 健臻公司 | 用於治療蛋白質病變之方法 |
| EP3275440B1 (en) * | 2015-03-25 | 2022-05-04 | National Center for Geriatrics and Gerontology | Novel oxadiazole derivative and pharmaceutical containing same |
-
2021
- 2021-03-23 KR KR1020227036699A patent/KR20230005168A/ko active Pending
- 2021-03-23 JP JP2022557683A patent/JP7838820B2/ja active Active
- 2021-03-23 CN CN202610125645.0A patent/CN121868303A/zh active Pending
- 2021-03-23 IL IL296649A patent/IL296649A/en unknown
- 2021-03-23 WO PCT/US2021/023653 patent/WO2021195066A2/en not_active Ceased
- 2021-03-23 BR BR112022019041A patent/BR112022019041A2/pt unknown
- 2021-03-23 EP EP21774687.4A patent/EP4125831A4/en active Pending
- 2021-03-23 US US17/906,893 patent/US20230285377A1/en active Pending
- 2021-03-23 AU AU2021241530A patent/AU2021241530A1/en active Pending
- 2021-03-23 CN CN202180035479.0A patent/CN115715189B/zh active Active
- 2021-03-23 MX MX2022011813A patent/MX2022011813A/es unknown
- 2021-03-23 CA CA3176609A patent/CA3176609A1/en active Pending
-
2022
- 2022-09-22 MX MX2026000122A patent/MX2026000122A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN121868303A (zh) | 2026-04-17 |
| MX2022011813A (es) | 2022-11-14 |
| CN115715189B (zh) | 2026-02-13 |
| KR20230005168A (ko) | 2023-01-09 |
| EP4125831A4 (en) | 2024-05-08 |
| AU2021241530A1 (en) | 2022-10-20 |
| EP4125831A2 (en) | 2023-02-08 |
| WO2021195066A2 (en) | 2021-09-30 |
| MX2026000122A (es) | 2026-02-03 |
| JP7838820B2 (ja) | 2026-04-01 |
| CN115715189A (zh) | 2023-02-24 |
| CA3176609A1 (en) | 2021-09-30 |
| US20230285377A1 (en) | 2023-09-14 |
| WO2021195066A3 (en) | 2021-10-21 |
| IL296649A (en) | 2022-11-01 |
| JP2023518838A (ja) | 2023-05-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022019041A2 (pt) | Inibidores de kcnt1 e métodos de uso | |
| BR112021022061A2 (pt) | Inibidores de kcnt1 e métodos de uso | |
| CL2024002067A1 (es) | Inhibidores y métodos de uso de kcnt1 | |
| BR112022017191A2 (pt) | Inibidores de kcnt1 e métodos de uso | |
| BR112023021068A2 (pt) | Compostos, composições e métodos para tratar câncer | |
| MX2023000360A (es) | Inhibidores de kcnt1 y metodos de uso. | |
| BR112022013388A2 (pt) | Inibidores de sarm1 | |
| WO2022140547A3 (en) | Kcnt1 inhibitors and methods of use | |
| BR112021017430A2 (pt) | Inibidores da proteína tirosina fosfatase e métodos de uso dos mesmos | |
| BR112022002442A2 (pt) | Terapias de imuno-oncologia com conjugados de il-2 | |
| BR112023002575A2 (pt) | Inibidores de sarm1 | |
| GT200600432A (es) | Compuestos de amino-5-[4-(difluorometoxi)fenil]-5-fenilimidazolona para la inhibicion de la beta-secretasa | |
| BR112021025781A2 (pt) | Composto, composição farmacêutica, método de tratamento de uma doença ou transtorno associado com um defeito no metabolismo de glioxilato, método de tratamento de uma doença ou transtorno associado com a enzima glicolato oxidase (go) ou alterações no metabolismo de oxalato e método para inibição da enzima go | |
| BR112022010082A2 (pt) | Composto de fórmula estrutural i ou sal do mesmo, composição farmacêutica, uso do composto e uso da composição farmacêutica | |
| PY1983118A (es) | Inhibidores de pde4 que contienen boro | |
| BR112023022284A2 (pt) | Composições de irna de protease transmembrana, serina 6 (tmprss6) e métodos de uso da mesma | |
| MX2022007441A (es) | Inhibidores de proteína tirosina fosfatasa y sus métodos de uso. | |
| BR112022019881A2 (pt) | Métodos, população de células, composição e kit | |
| CL2023003811A1 (es) | Oligonucleótidos antisentido pikfyve | |
| MX2024016116A (es) | Compuestos polimorficos y usos de estos | |
| JOP20230301A1 (ar) | تركيبات وطرق لتثبيط التعبير الوراثي عن مكون اختزال أميدوكسيم المتقدري 1 (marc1) | |
| BR112021022966A2 (pt) | Método para reduzir o tamanho do tumor | |
| BR112022015869A2 (pt) | Composto, composição farmacêutica, métodos para inibir a ceto-hexoquinase e de tratamento e/ou prevenção de uma doença ou distúrbio, e, uso de um composto | |
| BR112023018741A2 (pt) | Métodos de tratamento | |
| BR112022002522A2 (pt) | Tratamento de doenças neurológicas com inibidores do complemento |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |